The biotech company Immunos Therapeutics from Schlieren, Germany, which is researching a next-generation cancer drug, has secured $15.27 million (CHF15 million) in a financing round. At first glance, that may appear to be a modest amount in the international health care environment, but the circumstances surrounding the financing are very interesting.
Born2Invest is a digital media website covering the biotech industry, among others. Our companion app allows you to get your daily dose of financial news from industries like banking, cannabis, innovation in biotechnology.
The financing vehicle of a potential strategic partner
One particular aspect of the fundraising process is that Pfizer Ventures, the financing vehicle of a potential strategic partner, is already participating in this first stage of venture financing (Series A Financing). In addition to Pfizer, the Swiss venture capital firm Biomed Partners acts as co-leader of the financing. Other investors include Redalpine, Schroder Adveq, Wille Finance, and Bernina Bioinvest.
“We at Biomed Partners have successfully invested in several early cancer companies over the past seventeen years, including Glycart Biotechnology from Schlieremer, Germany,” said Markus Hosang of Biomed. Immunos and its new approach have particularly appealed to the company, as the treatment has the potential to help patients, alone or in combination with existing cancer drugs, that do not benefit from long-term current therapies.
Daniel Vasella as independent consultant
Markus Hosang of Biomed Partners and Michael Baran of Pfizer joined the Board of Directors of Immunos. Reinhard Ambros, former Managing Director of the Novartis Venture Fund, and Daniel Vasella, former CEO and Chairman of the Board of Directors of Novartis, will join as independent industry consultants.
In mid-October, Vasella announced his appointment to the board of directors of Numab, a biotech company based in Wädenswil, Germany. The former pharmaceutical manager appears to be ending the “dormancy period” following his commitment to Novartis.
Immunos is a spin-off of the Universities of Zurich and Basel. The company focuses on cancer therapies that target the innate immune system, the nonspecific or innate immune defense. The latest approved cancer therapies are aimed at checkpoint inhibitors that are designed to restart the immobilized immune system. The new funds will be used to finance the Phase I clinical trial of the application.
The novel drug is to be used in the future both as a combined application with checkpoint inhibitors and alone.
The biotech cluster prospers
This financing round brings the up-and-coming biotech cluster Schlieren back into focus. The Bio-Technopark is home to 45 biotech, MedTech and diagnostics companies. The best-known Schlieremer companies include Glycart, which was acquired by Roche in 2005 for $239.38 million (CHF235 million), Molecular Partners, which has been listed on the SIX since 2014, and Kuros, which was created in 2015 through a reverse merger with Cytos Biotechnology.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in Neue Burcher Zeitung, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Encomenda Invests €200,000 to Launch Telemedicine Startup Doctomatic
The fund led by Carlos Blanco and Oriol Juncosa has helped launch this new digital platform, called Doctomatic, for remote...
Burkina Faso: The European Investment Bank Strengthens its Partnership with CAPE
According to the Director-General of CAPE Burkina, the support of the EIB is one of the major factors that has...
The First Four Projects of the Civic Crowdfunding of Venice Were Launched
The first four civic crowdfunding projects in Venice were launched. The project "ONDEW - Let's face climate change together", is...
What Fintech Trends Set the Agenda for 2021 in Argentina
The fintech sector in Argentina has strongly developed during the pandemic. There are 238 fintech companies, i.e., almost three times...
Why Plant-Based Meat Could be the Future of the Food Market
Despite this incredible development and potential, vegetable meat is not the only alternative coming into play in this new era....
Cannabis2 weeks ago
Recreational Cannabis in Argentina, an Unavoidable Debate for the Congress in the Making
Featured2 weeks ago
PwC’s Climate Targets Were Validated by the SBTi Initiative
Crypto2 weeks ago
El Salvador’s Switch to Bitcoin Is Not the Cause of the Price Crash
Business2 weeks ago
Augmented Reality and Flooring in an App: XRA’s Double-Horned Unicorn